Bristol-Myers Squibb Co. (NYSE:BMY)
| CAPS Rating |
|
|---|---|
| Open | $32.06 |
| Previous Close | $32.08 |
| Daily Range | $31.80 - $32.13 |
| 52-Week Range | $24.97 - $35.44 |
| Market Cap | $54.65B |
| P/E Ratio | 17.10 |
| Dividend (Yield) | 1.36 (5.20%) |
| Volume | 4,931,375 |
| Average Daily Volume | 0 |
BMY
VS S&P 500 (SPY)
How do you think BMY will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
BMY Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
BMY News and Commentary
- 2 Stocks to Beat a Recession – The Motley Fool
- Modified Study, Same Bloody Results – The Motley Fool
- Higher Bleeding Haunts Merck Candidate - Analyst Blog – NASDAQ
- Earnings Scorecard: Bristol-Myers - Analyst Blog – NASDAQ
- YCHARTS DIVIDEND DAILY: Dividends Are Hot – Help For Finding Some Below – But Know the Risks, Too – YCharts
- Idenix Pharmaceuticals Shares Dropped: What You Need to Know – The Motley Fool
- Gilead Misses EPS Ests, Sales Up - Analyst Blog – NASDAQ
- Three Top-Notch Defensive Stocks – Minyanville
- Ten Big Pharma Stocks’ Juicy Dividend Payouts, With Cash-on-Hand as Cushion – YCharts
- This Drug Approval Is Good For the Industry – The Motley Fool
- Lipitor Loss? What's That? – The Motley Fool
- Got 401K? Part II in HD – Blogs @ The Motley Fool
- Patent Losses Hit Pfizer, Lilly As Both Await Alzheimer's Drug Data – SmartMoney
- FDA Approves KALYDECO™ (ivacaftor), the First Medicine to Treat the Underlying Cause of Cystic Fibrosis – Blog at The Motley Fool
- WSJ BLOG/Health: A.M. Vitals: J&J Shakes Up Oversight of Consumer Unit – SmartMoney
- Is Bristol-Myers Squibb Good Enough for You? – The Motley Fool
- WSJ BLOG/Health: A.M. Vitals: J&J Shakes Up Oversight of McNeil Unit – SmartMoney
- 3 Biotech Buyout Candidates for 2012 – The Motley Fool
- Has Gilead Sciences Become the Perfect Stock? – The Motley Fool
- Idenix Pharmaceuticals Shares Plunged Temporarily: What You Need to Know – The Motley Fool
RSS Headlines
Fool UK
